Impressive clinical progress of atopic dermatitis and renal dysfunction in Type 2 Diabetes (T2D) patient treated with cyclosporin A (CyA) and imeglimin (Twymeeg)

Kobayashi T, Bando H, Iwatsuki N, Sakamoto K and Ogawa T

Published on: 2023-04-15

Abstract

Current case was 65-year-old Type 2 Diabetes (T2D) male with stable situation of HbA1c 7.6%, creatinine 0.71 mg/dL. He developed atopic dermatitis (AD), and was treated in the university hospital with cyclosporin A (CyA). He took CyA intermittently due to impaired renal function of adverse effect (AE). HbA1c and creatinine were followed for years, and they showed exacerbation in Jan 2023 with 10.2% and 1.48 mg/dL. By the administration of vildagliptin and metformin (EquMet) and imeglimin (Twymeeg), his general situation was improved to 7.1% and 1.34 mg/dL. It suggested clinical efficacy of imeglimin for T2D and impaired renal function.